BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2022 7:22:19 AM | Browse: 730 | Download: 1371
Publication Name World Journal of Virology
Manuscript ID 75875
Country United States
ISSN 2220-3249 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Letter to the Editor
Article Title Cautious optimism in anticipation of hepatitis B curative therapies
Manuscript Source Invited Manuscript
All Author List Alla Turshudzhyan and Micheal Tadros
ORCID
Author(s) ORCID Number
Alla Turshudzhyan http://orcid.org/0000-0001-6867-7569
Micheal Tadros http://orcid.org/0000-0003-3118-3893
Funding Agency and Grant Number
Corresponding Author Alla Turshudzhyan, Consultant, N/A, N/A, Department of Medicine, University of Connecticut, 263 Farmington Avenue , Farmington, CT 06030-1235, United States. turshudzhyan@uchc.edu
Key Words Hepatitis B; Hepatitis B virus; Hepatitis B virus entry inhibitor; Bulevirtide; Transcription activator-like effector nucleases; Zinc-finger nucleases; Clustered regularly interspaced short palindromic repeats-associated 9; Nucleocapsid assembly modulators; Hepatitis B virus transcription inhibitors; Hepatitis B surface antigen release inhibitors
Core Tip Hepatitis B could become a curable disease in the near future. As our understanding of pathophysiology of hepatitis B infection advances, more therapeutic targets are becoming available. Many new therapies have only been investigated in small groups of patients with low viral load and without hepatotoxic injury or in patients with hepatitis D co-infection, which makes it difficult to predict efficacy and side effect profile when applied to the population of interest. Larger clinical trials in hepatitis B patients are needed to further investigate the emerging new therapies, so that more patients can safely benefit from them.
Publish Date 2022-07-22 07:22
Citation Turshudzhyan A, Tadros M. Cautious optimism in anticipation of hepatitis B curative therapies. World J Virol 2022; 11(4): 212-215
URL https://www.wjgnet.com/2220-3249/full/v11/i4/212.htm
DOI https://dx.doi.org/10.5501/wjv.v11.i4.212
Full Article (PDF) WJV-11-212.pdf
Full Article (Word) WJV-11-212.docx